01Already effective July 1, 2023 for dates of service on or after that date: Billing team: bill the new codes under the standard global billing procedures and edits, unless the table gives special billing guidance.
02Do not expect IHCP coverage for codes marked Noncovered in Table 1, because the IHCP does not cover those services for any programs.
03Get prior authorization before billing J1811, J1812, J1813, J1814, J2329 and J9381, which require it.
04For J9381 (teplizumab-mzwv), the member must be 8 years of age or older, have a Stage 2 type 1 diabetes diagnosis documented with at least two of the listed pancreatic islet cell autoantibodies and dysglycemia without overt hyperglycemia, have no history suggesting type 2 diabetes, have a CBC and liver enzyme tests documented within the past 30 days, have a negative pregnancy test documented within the past 30 days, and be prescribed by or in consultation with an endocrinologist.
05Report NDC for the J codes marked Yes in the NDC column.
06Bill skin-substitute codes Q4272 through Q4284 at the flat statewide per-unit rate and as the table indicates for podiatrists (provider specialty 140) and revenue code 636.
07Ambulance providers (provider specialty 260) may bill J2329, J2371 and J2372 as listed.
08Bill J7213 as a code carved out of managed care and separately reimbursable outside the inpatient DRG.
09Use the alternate codes in Table 7 for end-dated codes C9146, C9148 and C9149.
10Pricing for the new codes is to be determined, and the IHCP will issue a separate publication with pricing after final calculations.
11Direct fee-for-service billing questions to Gainwell Technologies at 800-457-4584, and direct fee-for-service prior authorization questions to Kepro Customer Service at 866-725-9991.
12Managed care reimbursement, prior authorization and billing questions go to the managed care entity in which the member is enrolled.
13The bulletin notes that procedure code J9321 was removed from Table 1.